The administration of a pharmaceutical composition comprising an A3 adenosine (A3AR) agonist has been found to alleviate the symptoms of neuropathic pain regardless of the cause or location, or ...

Piclidenoson, an orally administered drug, has demonstrated a safety and efficacy profile in a Phase III trial for psoriasis ...

We have been exploring the potential of the neuromodulator, adenosine, to reduce excessive dopamine signaling that contributes to the development and persistence of psychostimulant abuse. Dopamine’s ...

Exploration of adenosine mechanism revealed adenosine receptors as a potentially useful target of therapy in RA.

Exploration of adenosine mechanism revealed adenosine receptors as a potentially useful target of therapy in RA. Principal signaling pathways activated by adenosine receptors. AC: Adenylate ...

Oral Opportunity in PsO (US) 2024, highlights a shifting landscape in the treatment for moderate-to-severe PsO. As emerging oral therapies gain traction, the study underscores their potential to ...

We are very pleased to work productively with the team at Vetbiolix.” stated Can-Fite VP of business Development Dr. Sari ...

My research interests are in the general area of the integrative physiology of obesity and diabetes. I have published original research articles on the role of melanocortin receptors expressed in the ...

The chemical is a 39-amino-acid linear peptide with a C20 fatty acid component. In animal studies, Tirzepatide has been hypothesized to act as a biased agonist at the GLP-1 receptor, causing it to ...

Beta-receptor agonists cause insulin resistance, whereas alpha-receptor agonists reduce insulin ... The digestion of glucose leads to the production of Cyclic Adenosine Monophosphate (cAMP), causing ...